Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MMP13 | P45452 | 8/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.31 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL765660 | 0.75 | CYP4F2 (0.52) | — | |
| SCHEMBL6810513 | 0.68 | NR3C2 (0.43) | — | |
| SCHEMBL2489586 | 0.68 | MEN1 (0.35) | ALDH1A1L3MBTL1MEN1KMT2AMMP13 | |
| SCHEMBL754174 | 0.68 | LIPG (0.46) | ALDH1A1L3MBTL1MEN1KMT2AMMP13 | |
| SCHEMBL755368 | 0.66 | HRH3 (0.39) | ALDH1A1L3MBTL1MEN1KMT2AMMP13 | |
| SCHEMBL754143 | 0.65 | PARP1 (0.33) | ALDH1A1L3MBTL1SMN1; SMN2 | |
| SCHEMBL31132915 | 0.60 | MEN1 (0.48) | ALDH1A1L3MBTL1MEN1KMT2AKDM4E | |
| SCHEMBL753246 | 0.60 | MEN1 (0.59) | ALDH1A1L3MBTL1MEN1KMT2AKDM4E | |
| SCHEMBL4023471 | 0.60 | BCAT2 (0.67) | ALDH1A1L3MBTL1MEN1KMT2AKDM4E | |
| SCHEMBL12937247 | 0.59 | MEN1 (0.53) | ALDH1A1L3MBTL1MEN1KMT2AMMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1422218-B1 | ANTIVIRAL AGENT | SHIONOGI & CO (JP) | 2012-03-21 | — | — | EP | disclosed |